课题基金 / 基金详情

A programmable, cell-agnostic DNA nano-technology platform for CRISPR gene editing

A programmable, cell-agnostic DNA nano-technology platform for CRISPR gene editing
用于 CRISPR 基因编辑的可编程、与细胞无关的 DNA 纳米技术平台
批准号:
EP/V048058/1
负责人:
Lorenzo Di Michele
金额:
$25.69万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2021
资助国家:
英国
项目状态:
已结题
起止时间:
2021 至 --

项目摘要

项目成果

Lorenzo Di Michele的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
CRISPR-Cas9 gene editing has warranted its developers the 2020 Nobel Prize for Chemistry, in view of the massive impact that this technology is having on biological, biotechnological and medical research. In particular CRISPR gene editing is central to next generation cell-based therapies to treat cancer and other diseases, in which some of the patient's cells are extracted, genetically modified to fulfil specific functions, and then re-injected into the patient. This process is however time consuming and very costly, limiting the diffusion of these potentially life-saving therapies. One of the reasons behind the prohibitive costs is the low efficiency with which one can deliver to the cells the biological machinery required to perform CRISPR gene editing, both at scale and without excessive toxicity (leading to cell death).In this project, we will develop a novel and alternative approach to delivering CRISPR machinery to mammalian cells in vitro. Our approach will rely on specifically designed vectors, which we dub Editosomes. These are microscopic enclosures constructed from lipid membranes, similar to cell membranes, and containing large quantities of the CRISPR machinery.For Editosomes to deliver the machinery to the target cells the two would have to fuse. We will induce fusion by decorating both Editosomes and the target cells with artificial "fusogenic" nanomachines, that by binding to each other bring the cell and Editosome membranes to within a very short distance, ultimately making them merge. The fusogenic nanostructures will be constructed from synthetic DNA molecules, which are particularly suitable for engineering nanodevices in view of the very high selectivity and programmability of the base-pairing interactions.We envisage that Editosome technology will have a direct and profound impact on our ability to perform high-throughput, efficient, CRISPR gene editing in vivo, and thus on the accessibility and economic sustainability of the therapeutic technologies that rely on it.Additionally, we will clarify fundamental aspects of the (bio)physics underling lipid membrane stability, fusion, and the ability of DNA nanostructures to modulate them.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1039/d2sm00863g
发表时间: 2022-09-28
期刊: Soft matter
影响因子: 3.4
作者: []
通讯作者:
2022BBSRC-NSF/BIO: Self-replicating synthetic cells programmed by RNA
  • 批准号:
    BB/Y000196/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $56.15万
  • 财政年份:
    2024
  • 负责人:
    Lorenzo Di Michele
  • 依托单位:
EPSRC New Horizons 2021: Engineering synthetic synapses between artificial and biological cells.
  • 批准号:
    EP/X018903/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $25.78万
  • 财政年份:
    2023
  • 负责人:
    Lorenzo Di Michele
  • 依托单位:
Japan_IPAP - Top-down meets bottom-up: Designer membrane-less organelles from condensation of synthetic RNA nanostructure
  • 批准号:
    BB/X012557/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $19.27万
  • 财政年份:
    2023
  • 负责人:
    Lorenzo Di Michele
  • 依托单位:
国内基金
海外基金
全细胞疫苗Cell@MnO2的乳腺癌术后免疫响应监测与放射免疫治疗研究
  • 批准号:
    QN25H220002
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    顾媛
  • 依托单位:
染色体外环状DNA以cell-in-cell途径促进基因横向传递和扩增的研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    15.0万元
  • 批准年份:
    2024
  • 负责人:
    王锐智
  • 依托单位:
GMFG/F-actin/cell adhesion 轴驱动 EHT 在造 血干细胞生成中的作用及机制研究
  • 批准号:
    TGY24H080011
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    李鸿鹄
  • 依托单位:
糖尿病ED中成纤维细胞衰老调控内皮细胞线粒体稳态失衡的机制研究
  • 批准号:
    82371634
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    赵福军
  • 依托单位: